Vaxdyn Overview
- Year Founded
-
2011

- Status
-
Private
- Employees
-
9

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$2.71M
- Investors
-
8
Vaxdyn General Information
Description
Developer of immunotherapies and vaccines intended to prevent infectious diseases. The company's vaccines use antigens, immunomodulators, nanoparticles, and monoclonal antibodies to fight bacterial infections, enabling doctors to decrease the impact of infections caused by drug-resistant pathogens on public health.
Contact Information
Website
www.vaxdyn.comCorporate Office
- Parque Ciudad del Conocimiento. calle Manuel Manaute Humanes s/n.
- Edificio central, despacho 6
- 41704 Dos Hermanas
- Spain
Corporate Office
- Parque Ciudad del Conocimiento. calle Manuel Manaute Humanes s/n.
- Edificio central, despacho 6
- 41704 Dos Hermanas
- Spain
Vaxdyn Timeline
Vaxdyn Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Grant | 13-Mar-2024 | $2.71M | Completed | Generating Revenue | ||
4. Seed Round | 07-Apr-2022 | Completed | Generating Revenue | |||
3. Grant | 07-Jul-2020 | Completed | Generating Revenue | |||
2. Secondary Transaction - Private | $1.2M | Completed | Startup | |||
1. Seed Round | 01-Jan-2016 | $1.2M | $1.2M | Completed | Startup |
Vaxdyn Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | ||||||||
Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Vaxdyn Patents
Vaxdyn Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4169529-A1 | Lipopolysaccharide (lps) deficient acinetobacter baumannii multivalent vaccine | Inactive | 20-Oct-2021 | ||
EP-4419135-A1 | Lipopolysaccharide (lps) deficient acinetobacter baumannii multivalent vaccine | Pending | 20-Oct-2021 | ||
CA-3235160-A1 | Lipopolysaccharide (lps) deficient acinetobacter baumannii multivalent vaccine | Pending | 20-Oct-2021 | ||
US-11160856-B2 | Vaccine against acinetobacter baumannii based on cellular components deficient in lipopolysaccharide | Active | 05-May-2014 | ||
US-20170065700-A1 | Vaccine against acinetobacter baumannii based on cellular components deficient in lipopolysaccharide | Inactive | 05-May-2014 | A61K39/104 |
Vaxdyn Signals
Vaxdyn Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
European Innovation Council Fund | Venture Capital | Minority | ||
Arquimea Group | Corporation | Minority | ||
Bionova Capital | Venture Capital | Minority | ||
Botín Foundation | Limited Partner | Minority | ||
Laboratorio Reig Jofré | Corporation | Minority |
Vaxdyn FAQs
-
When was Vaxdyn founded?
Vaxdyn was founded in 2011.
-
Where is Vaxdyn headquartered?
Vaxdyn is headquartered in Dos Hermanas, Spain.
-
What is the size of Vaxdyn?
Vaxdyn has 9 total employees.
-
What industry is Vaxdyn in?
Vaxdyn’s primary industry is Drug Discovery.
-
Is Vaxdyn a private or public company?
Vaxdyn is a Private company.
-
What is Vaxdyn’s current revenue?
The current revenue for Vaxdyn is
. -
How much funding has Vaxdyn raised over time?
Vaxdyn has raised $1.8M.
-
Who are Vaxdyn’s investors?
European Innovation Council Fund, Arquimea Group, Bionova Capital, Botín Foundation, and Laboratorio Reig Jofré are 5 of 8 investors who have invested in Vaxdyn.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »